Patients suffering from hematological malignancies such as Non Hodgkin’s Lymphoma, Hodgkin Lymphoma or Multiple Myeloma are eligible for high-dose chemotherapy and autologous hematopoietic stem cell transplantation (HSCT). Despite a range of options for collecting sufficient numbers of HSC for transplantation, approximately 10-30% of patients eligible for HSCT are not able to collect the minimum target cell count. These patients are considered to be poor mobilizers. The novel agent plerixafor, is expected to improve the mobilization of HSC into the peripheral blood when added to standard treatment in order to provide poor mobilizers with access to HSCTand hight-dose chemotherapy.